FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080403196> ?p ?o ?g. }

• W2080403196 endingPage "2139" @default.
• W2080403196 startingPage "2138" @default.
• W2080403196 abstract "HomeStrokeVol. 33, No. 8Aspirin Therapy Should Be First-Line Treatment in Secondary Prevention of Stroke—Against Free AccessArticle CommentaryPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessArticle CommentaryPDF/EPUBAspirin Therapy Should Be First-Line Treatment in Secondary Prevention of Stroke—Against Hans-Christoph Diener, MD Hans-Christoph DienerHans-Christoph Diener From the Department of Neurology, University Essen, Essen, Germany. Search for more papers by this author Originally published1 Aug 2002https://doi.org/10.1161/01.STR.0000023102.03179.30Stroke. 2002;33:2138–2139Patients with transient ischemic attack (TIA) are at high risk for an ischemic stroke,1 and patients who have already suffered a stroke are at high risk for stroke recurrence. Aspirin leads only to a modest reduction both in the risk of stroke (23%) and in reducing the combined end point of stroke, myocardial infection (MI), or vascular death (18%).2Ticlopidine is more effective than aspirin. A large multicenter trial compared a daily dose of 500 mg ticlopidine and 1300 mg/d aspirin in 3069 patients with TIA or minor stroke.3 This study was associated with a statistically significant 21% reduction (P=0.024) in fatal or nonfatal stroke risk at 3 years in patients who received ticlopidine versus aspirin. The relative risk reduction of the combined outcome of stroke, MI, or vascular death was reduced by 9% in favor of ticlopidine, which was not statistically significant. Ticlopidine, however, can lead to neutropenia in up to 0.8% of patients3,4 and therefore is no longer the drug of choice.Clopidogrel is an antiplatelet agent that is chemically related to ticlopidine. A pivotal randomized, blinded, international trial, Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE), examined the relative safety and efficacy of daily doses of 75 mg clopidogrel versus 325 mg aspirin in nearly 20 000 patients with stroke, MI, or peripheral arterial disease.5 The results of the trial showed that clopidogrel was more effective than aspirin in preventing a combined end point of ischemic stroke, MI, or vascular death. The trialists found a significant 8.7% reduction in relative risk (P=0.043) for clopidogrel versus aspirin. Although the CAPRIE trial was not powered to detect treatment differences within patient subgroups, a subgroup analysis, which was not part of the original design, was performed. Overall, when the results for these subgroups were examined, there was no significant difference between clopidogrel and aspirin in patients with stroke or MI. There was, however, a significant benefit favoring clopidogrel in patients with peripheral arterial disease.The combination of aspirin plus slow-release dipyridamole was investigated in the Second European Stroke Prevention Study (ESPS-2).6 ESPS-2 analyzed 6602 stroke or TIA patients who were randomly assigned to 4 treatment arms: placebo; aspirin alone (25 mg twice daily); extended-release dipyridamole alone (200 mg twice daily); or aspirin (25 mg twice daily) plus extended-release dipyridamole (200 mg twice daily). The trial showed additive effects of aspirin and dipyridamole. The aspirin-plus-dipyridamole regimen of ESPS-2 produced a statistically significant 37% reduction (P=0.00l) in risk of fatal or nonfatal stroke over 2 years compared with placebo, similar to the risk reduction of the earlier ESPS-1 trial (38%).7 Neither aspirin nor dipyridamole or the combination reduced mortality.8Taken together, these study results show that the combination of aspirin plus dipyridamole is superior to aspirin alone in the prevention of stroke after TIA or stroke. The bleeding risk is not higher than with aspirin alone.6 Therefore, aspirin plus dipyridamole is the first-line treatment for secondary prevention of stroke. Clopidogrel is superior to aspirin for a combined end point of stroke, MI, and vascular death and is first-line treatment for high-risk patients with multiple vascular risk factors (eg, peripheral arterial disease). Whether the combination of clopidogrel plus aspirin is superior to aspirin alone is under investigation (MATCH trial).The opinions expressed in this editorial are not necessarily those of the editors or of the American Stroke Association.FootnotesCorrespondence to Dr Hans-Christoph Diener, Department of Neurology, University Essen, Hufelandstrasse 55, 45122 Essen, Germany. E-mail [email protected] References 1 Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA. 2000; 284: 2901–2906.CrossrefMedlineGoogle Scholar2 Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994; 308: 81–106.CrossrefMedlineGoogle Scholar3 Hass WK, Easton JD, Adams HP, Pryse-Phillips W, Molony BA, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke. N Engl J Med. 1989; 321: 501–507.CrossrefMedlineGoogle Scholar4 Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AGG. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989; 1: 1215–1220.CrossrefMedlineGoogle Scholar5 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996; 348: 1329–1339.CrossrefMedlineGoogle Scholar6 Diener HC, Cuhna L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996; 143: 1–13.CrossrefMedlineGoogle Scholar7 The ESPS Group. The European Stroke Prevention Study (ESPS): principal end- points. Lancet. 1987; 2: 1351–1354.MedlineGoogle Scholar8 Diener HC, Forbes C, Riekkinen PJ, Sivenius J, Smets P, Lowenthal A, and the ESPS Group. European Stroke Prevention Study 2: efficacy and safety data. J Neurol Sci. 1997; 151 (suppl): S1–S77.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Li Z, Yu Z, Wang D, Ju W, Zhan X, Wu Q, Wu X, Cong H and Man H (2013) Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases, Neurological Research, 10.1179/174313208X300369, 30:4, (366-369), Online publication date: 1-May-2008. Reiter R and Jilma B (2005) Platelets and new antiplatelet drugs, Therapy, 10.2217/14750708.2.3.465, 2:3, (465-502), Online publication date: 1-May-2005. Matchar D, Samsa G and Liu S (2005) Cost-Effectiveness of Antiplatelet Agents in Secondary Stroke Prevention: The Limits of Certainty, Value in Health, 10.1111/j.1524-4733.2005.00050.x, 8:5, (572-580), Online publication date: 1-Sep-2005. Zaher C, Schloss S, George D, Poret A and Shah H (2005) Characterization of Ischemic Events and Use of Prescription Antiplatelet and Anticoagulant Agents After Stroke or Transient Ischemic Attack, Journal of Stroke and Cerebrovascular Diseases, 10.1016/j.jstrokecerebrovasdis.2005.03.001, 14:4, (145-151), Online publication date: 1-Jul-2005. Lee J, Park S, Lee W and Hong K (2013) Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats, Neurological Research, 10.1179/016164105X17134, 27:5, (483-492), Online publication date: 1-Jul-2005. Koennecke H (2004) Secondary Prevention of Stroke, CNS Drugs, 10.2165/00023210-200418040-00003, 18:4, (221-241), . Cía Gómez P and Cía Blasco P (2003) Perspectivas terapéuticas de la doble antiagregación plaquetaria, Revista Clínica Española, 10.1016/S0014-2565(03)71301-0, 203:8, (388-390), Online publication date: 1-Jan-2003. Eimil M and Egido J (2003) Ataque isquémico transitorio, FMC - Formación Médica Continuada en Atención Primaria, 10.1016/S1134-2072(03)75904-0, 10:5, (295-303), Online publication date: 1-Jan-2003. &NA; (2002) Aspirin: first choice for preventing recurrent stroke?, Inpharma Weekly, 10.2165/00128413-200213560-00005, &NA;:1356, (3), Online publication date: 1-Sep-2002. August 2002Vol 33, Issue 8 Advertisement Article InformationMetrics https://doi.org/10.1161/01.STR.0000023102.03179.30PMID: 12154277 Originally publishedAugust 1, 2002 Keywordsclopidogrelaspirinstroke preventionticlopidinedipyridamolePDF download Advertisement" @default.
• W2080403196 created "2016-06-24" @default.
• W2080403196 creator A5033104412 @default.
• W2080403196 date "2002-08-01" @default.
• W2080403196 modified "2023-10-16" @default.
• W2080403196 title "Aspirin Therapy Should Be First-Line Treatment in Secondary Prevention of Stroke—Against" @default.
• W2080403196 cites W10734288 @default.
• W2080403196 cites W2011274865 @default.
• W2080403196 cites W2111089169 @default.
• W2080403196 cites W2148132508 @default.
• W2080403196 cites W2318352361 @default.
• W2080403196 cites W311320695 @default.
• W2080403196 cites W4239471829 @default.
• W2080403196 doi "https://doi.org/10.1161/01.str.0000023102.03179.30" @default.
• W2080403196 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12154277" @default.
• W2080403196 hasPublicationYear "2002" @default.
• W2080403196 type Work @default.
• W2080403196 sameAs 2080403196 @default.
• W2080403196 citedByCount "13" @default.
• W2080403196 countsByYear W20804031962017 @default.
• W2080403196 crossrefType "journal-article" @default.
• W2080403196 hasAuthorship W2080403196A5033104412 @default.
• W2080403196 hasBestOaLocation W20804031961 @default.
• W2080403196 hasConcept C126322002 @default.
• W2080403196 hasConcept C127413603 @default.
• W2080403196 hasConcept C141071460 @default.
• W2080403196 hasConcept C177713679 @default.
• W2080403196 hasConcept C2777628954 @default.
• W2080403196 hasConcept C2780645631 @default.
• W2080403196 hasConcept C3019417119 @default.
• W2080403196 hasConcept C3020199598 @default.
• W2080403196 hasConcept C541997718 @default.
• W2080403196 hasConcept C71924100 @default.
• W2080403196 hasConcept C78519656 @default.
• W2080403196 hasConceptScore W2080403196C126322002 @default.
• W2080403196 hasConceptScore W2080403196C127413603 @default.
• W2080403196 hasConceptScore W2080403196C141071460 @default.
• W2080403196 hasConceptScore W2080403196C177713679 @default.
• W2080403196 hasConceptScore W2080403196C2777628954 @default.
• W2080403196 hasConceptScore W2080403196C2780645631 @default.
• W2080403196 hasConceptScore W2080403196C3019417119 @default.
• W2080403196 hasConceptScore W2080403196C3020199598 @default.
• W2080403196 hasConceptScore W2080403196C541997718 @default.
• W2080403196 hasConceptScore W2080403196C71924100 @default.
• W2080403196 hasConceptScore W2080403196C78519656 @default.
• W2080403196 hasIssue "8" @default.
• W2080403196 hasLocation W20804031961 @default.
• W2080403196 hasLocation W20804031962 @default.
• W2080403196 hasOpenAccess W2080403196 @default.
• W2080403196 hasPrimaryLocation W20804031961 @default.
• W2080403196 hasRelatedWork W1584895772 @default.
• W2080403196 hasRelatedWork W2012850193 @default.
• W2080403196 hasRelatedWork W2022886132 @default.
• W2080403196 hasRelatedWork W2047171142 @default.
• W2080403196 hasRelatedWork W2064286441 @default.
• W2080403196 hasRelatedWork W2089370436 @default.
• W2080403196 hasRelatedWork W2147909728 @default.
• W2080403196 hasRelatedWork W2186423341 @default.
• W2080403196 hasRelatedWork W2741762255 @default.
• W2080403196 hasRelatedWork W2810872557 @default.
• W2080403196 hasVolume "33" @default.
• W2080403196 isParatext "false" @default.
• W2080403196 isRetracted "false" @default.
• W2080403196 magId "2080403196" @default.
• W2080403196 workType "article" @default.